Switch to:
Also traded in: France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.27
ABBV's Cash to Debt is ranked lower than
85% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.45 vs. ABBV: 0.27 )
Ranked among companies with meaningful Cash to Debt only.
ABBV' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 0.65 Max: No Debt
Current: 0.27
Equity to Asset 0.09
ABBV's Equity to Asset is ranked lower than
97% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. ABBV: 0.09 )
Ranked among companies with meaningful Equity to Asset only.
ABBV' s Equity to Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.13 Max: 0.69
Current: 0.09
-0.01
0.69
Interest Coverage 10.13
ABBV's Interest Coverage is ranked lower than
65% of the 467 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.06 vs. ABBV: 10.13 )
Ranked among companies with meaningful Interest Coverage only.
ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 5027.47 Max: 9999.99
Current: 10.13
7.95
9999.99
F-Score: 7
Z-Score: 2.37
M-Score: -2.14
WACC vs ROIC
12.38%
26.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 34.18
ABBV's Operating margin (%) is ranked higher than
94% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. ABBV: 34.18 )
Ranked among companies with meaningful Operating margin (%) only.
ABBV' s Operating margin (%) Range Over the Past 10 Years
Min: 17.09  Med: 30.15 Max: 34.7
Current: 34.18
17.09
34.7
Net-margin (%) 23.03
ABBV's Net-margin (%) is ranked higher than
90% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.15 vs. ABBV: 23.03 )
Ranked among companies with meaningful Net-margin (%) only.
ABBV' s Net-margin (%) Range Over the Past 10 Years
Min: 8.89  Med: 24.35 Max: 32.62
Current: 23.03
8.89
32.62
ROE (%) 134.66
ABBV's ROE (%) is ranked higher than
100% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. ABBV: 134.66 )
Ranked among companies with meaningful ROE (%) only.
ABBV' s ROE (%) Range Over the Past 10 Years
Min: 24.85  Med: 56.91 Max: 199.32
Current: 134.66
24.85
199.32
ROA (%) 11.31
ABBV's ROA (%) is ranked higher than
81% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. ABBV: 11.31 )
Ranked among companies with meaningful ROA (%) only.
ABBV' s ROA (%) Range Over the Past 10 Years
Min: 6.26  Med: 16.89 Max: 39.54
Current: 11.31
6.26
39.54
ROC (Joel Greenblatt) (%) 249.54
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.16 vs. ABBV: 249.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABBV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 74.13  Med: 142.15 Max: 170.07
Current: 249.54
74.13
170.07
Revenue Growth (3Y)(%) 3.90
ABBV's Revenue Growth (3Y)(%) is ranked lower than
56% of the 602 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ABBV: 3.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABBV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.90 Max: 5.7
Current: 3.9
0
5.7
EBITDA Growth (3Y)(%) -10.50
ABBV's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ABBV: -10.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABBV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -10.50 Max: 2.2
Current: -10.5
0
2.2
EPS Growth (3Y)(%) -20.30
ABBV's EPS Growth (3Y)(%) is ranked lower than
81% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. ABBV: -20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABBV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -20.30 Max: -1
Current: -20.3
» ABBV's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ABBV Guru Trades in Q2 2015

First Eagle Investment 678,300 sh (New)
Louis Moore Bacon 25,000 sh (New)
Steven Cohen 1,245,500 sh (+760.15%)
Larry Robbins 17,855,941 sh (+630.71%)
David Dreman 28,292 sh (+193.03%)
Scott Black 151,910 sh (+27.14%)
Pioneer Investments 2,701,617 sh (+14.08%)
Louis Moore Bacon 100,000 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jeff Auxier 19,171 sh (unchged)
Tom Russo 86,718 sh (unchged)
Westport Asset Management Sold Out
Manning & Napier Advisors, Inc Sold Out
Murray Stahl 32,060 sh (-0.01%)
Ken Fisher 1,006,679 sh (-0.40%)
Mairs and Power 268,776 sh (-1.19%)
Mario Gabelli 46,562 sh (-1.38%)
Dodge & Cox 34,255 sh (-2.28%)
Lee Ainslie 3,950 sh (-8.56%)
NWQ Managers 1,583,682 sh (-13.88%)
PRIMECAP Management 2,799,320 sh (-24.97%)
Paul Tudor Jones 6,500 sh (-35.45%)
Joel Greenblatt 33,605 sh (-93.95%)
Jim Simons 8,200 sh (-99.31%)
» More
Q3 2015

ABBV Guru Trades in Q3 2015

Jim Simons 2,933,756 sh (+35677.51%)
Paul Tudor Jones 49,480 sh (+661.23%)
Joel Greenblatt 73,037 sh (+117.34%)
First Eagle Investment 1,056,150 sh (+55.71%)
David Dreman 31,197 sh (+10.27%)
Murray Stahl 35,121 sh (+9.55%)
Jeff Auxier 20,272 sh (+5.74%)
Scott Black 154,855 sh (+1.94%)
Tom Russo 86,718 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Lee Ainslie Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Mairs and Power 266,936 sh (-0.68%)
Dodge & Cox 33,255 sh (-2.92%)
NWQ Managers 1,526,806 sh (-3.59%)
Mario Gabelli 43,930 sh (-5.65%)
Ken Fisher 927,959 sh (-7.82%)
Larry Robbins 16,170,903 sh (-9.44%)
PRIMECAP Management 2,511,945 sh (-10.27%)
Pioneer Investments 2,286,962 sh (-15.35%)
» More
Q4 2015

ABBV Guru Trades in Q4 2015

First Pacific Advisors 75,500 sh (New)
Louis Moore Bacon 36,243 sh (New)
John Paulson 139,700 sh (New)
Joel Greenblatt 204,171 sh (+179.54%)
Murray Stahl 36,019 sh (+2.56%)
Ken Fisher 935,104 sh (+0.77%)
Tom Russo 86,718 sh (unchged)
Dodge & Cox 33,255 sh (unchged)
Jeff Auxier 20,272 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
First Eagle Investment Sold Out
Mairs and Power 266,811 sh (-0.05%)
Mario Gabelli 40,600 sh (-7.58%)
David Dreman 26,267 sh (-15.80%)
Larry Robbins 13,544,815 sh (-16.24%)
Paul Tudor Jones 32,925 sh (-33.46%)
Pioneer Investments 1,150,074 sh (-49.71%)
NWQ Managers 754,413 sh (-50.59%)
PRIMECAP Management 1,165,045 sh (-53.62%)
Scott Black 40,798 sh (-73.65%)
Jim Simons 582,756 sh (-80.14%)
» More
Q1 2016

ABBV Guru Trades in Q1 2016

Lee Ainslie 43,170 sh (New)
Joel Greenblatt 645,835 sh (+216.32%)
Jim Simons 1,563,056 sh (+168.22%)
David Dreman 30,542 sh (+16.28%)
Pioneer Investments 1,261,434 sh (+9.68%)
NWQ Managers 781,850 sh (+3.64%)
Scott Black 41,959 sh (+2.85%)
Jeff Auxier 20,572 sh (+1.48%)
Larry Robbins 13,686,588 sh (+1.05%)
Mairs and Power 268,191 sh (+0.52%)
Murray Stahl 36,154 sh (+0.37%)
Robert Bruce 232,915 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
Louis Moore Bacon Sold Out
John Paulson Sold Out
Dodge & Cox 33,232 sh (-0.07%)
PRIMECAP Management 1,022,845 sh (-12.21%)
Mario Gabelli 35,460 sh (-12.66%)
Ken Fisher 743,284 sh (-20.51%)
First Pacific Advisors 56,050 sh (-25.76%)
Tom Russo 21,718 sh (-74.96%)
Paul Tudor Jones 4,100 sh (-87.55%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.

AbbVie Inc was incorporated in Delaware on April 10, 2012, and is a wholly owned subsidiary of Abbott. The company is a research-based biopharmaceutical company with portfolio of proprietary products including a broad line of adult and pediatric pharmaceuticals. The company discovers, develops, manufactures and sells proprietary pharmaceutical products. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. AbbVie operates in one business segment-pharmaceutical products. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics.

Ratios

vs
industry
vs
history
P/E(ttm) 18.89
ABBV's P/E(ttm) is ranked higher than
70% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.44 vs. ABBV: 18.89 )
Ranked among companies with meaningful P/E(ttm) only.
ABBV' s P/E(ttm) Range Over the Past 10 Years
Min: 9.86  Med: 19.93 Max: 63.84
Current: 18.89
9.86
63.84
Forward P/E 11.21
ABBV's Forward P/E is ranked higher than
71% of the 90 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.95 vs. ABBV: 11.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.83
ABBV's PE(NRI) is ranked higher than
70% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.81 vs. ABBV: 18.83 )
Ranked among companies with meaningful PE(NRI) only.
ABBV' s PE(NRI) Range Over the Past 10 Years
Min: 9.85  Med: 19.94 Max: 63.95
Current: 18.83
9.85
63.95
Price/Owner Earnings (ttm) 15.35
ABBV's Price/Owner Earnings (ttm) is ranked higher than
82% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.19 vs. ABBV: 15.35 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABBV' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.14  Med: 20.06 Max: 53.75
Current: 15.35
13.14
53.75
P/B 21.76
ABBV's P/B is ranked lower than
97% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. ABBV: 21.76 )
Ranked among companies with meaningful P/B only.
ABBV' s P/B Range Over the Past 10 Years
Min: 15.73  Med: 20.40 Max: 77.07
Current: 21.76
15.73
77.07
P/S 4.32
ABBV's P/S is ranked lower than
62% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. ABBV: 4.32 )
Ranked among companies with meaningful P/S only.
ABBV' s P/S Range Over the Past 10 Years
Min: 2.83  Med: 4.32 Max: 5.67
Current: 4.32
2.83
5.67
PFCF 13.59
ABBV's PFCF is ranked higher than
79% of the 199 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.71 vs. ABBV: 13.59 )
Ranked among companies with meaningful PFCF only.
ABBV' s PFCF Range Over the Past 10 Years
Min: 8.66  Med: 14.62 Max: 38.18
Current: 13.59
8.66
38.18
POCF 12.73
ABBV's POCF is ranked higher than
71% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.71 vs. ABBV: 12.73 )
Ranked among companies with meaningful POCF only.
ABBV' s POCF Range Over the Past 10 Years
Min: 8.2  Med: 13.48 Max: 31.6
Current: 12.73
8.2
31.6
EV-to-EBIT 15.72
ABBV's EV-to-EBIT is ranked higher than
68% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.64 vs. ABBV: 15.72 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 15.70 Max: 41
Current: 15.72
10.2
41
EV-to-EBITDA 14.45
ABBV's EV-to-EBITDA is ranked higher than
65% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.81 vs. ABBV: 14.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.90 Max: 33.1
Current: 14.45
8.6
33.1
Current Ratio 1.56
ABBV's Current Ratio is ranked lower than
70% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. ABBV: 1.56 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.04 Max: 2.82
Current: 1.56
1.22
2.82
Quick Ratio 1.39
ABBV's Quick Ratio is ranked lower than
65% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. ABBV: 1.39 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.84 Max: 2.65
Current: 1.39
1.06
2.65
Days Inventory 118.44
ABBV's Days Inventory is ranked lower than
52% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. ABBV: 118.44 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 79.47 Max: 93.77
Current: 118.44
35.55
93.77
Days Sales Outstanding 72.96
ABBV's Days Sales Outstanding is ranked higher than
51% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.15 vs. ABBV: 72.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.3  Med: 78.73 Max: 93.3
Current: 72.96
68.3
93.3
Days Payable 118.31
ABBV's Days Payable is ranked higher than
75% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.47 vs. ABBV: 118.31 )
Ranked among companies with meaningful Days Payable only.
ABBV' s Days Payable Range Over the Past 10 Years
Min: 30.33  Med: 115.54 Max: 175.86
Current: 118.31
30.33
175.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.44
ABBV's Dividend Yield is ranked higher than
85% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. ABBV: 3.44 )
Ranked among companies with meaningful Dividend Yield only.
ABBV' s Dividend Yield Range Over the Past 10 Years
Min: 0.85  Med: 2.89 Max: 3.84
Current: 3.44
0.85
3.84
Dividend Payout 0.63
ABBV's Dividend Payout is ranked lower than
77% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. ABBV: 0.63 )
Ranked among companies with meaningful Dividend Payout only.
ABBV' s Dividend Payout Range Over the Past 10 Years
Min: 0.55  Med: 0.66 Max: 1.36
Current: 0.63
0.55
1.36
Forward Dividend Yield 3.64
ABBV's Forward Dividend Yield is ranked higher than
83% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. ABBV: 3.64 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.45
ABBV's Yield on cost (5-Year) is ranked higher than
73% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. ABBV: 3.45 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABBV' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.85  Med: 2.88 Max: 3.84
Current: 3.45
0.85
3.84
3-Year Average Share Buyback Ratio -0.30
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. ABBV: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: -0.20 Max: 0
Current: -0.3
-0.3
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.00
ABBV's Price/Median PS Value is ranked higher than
64% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. ABBV: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ABBV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.68  Med: 0.99 Max: 1.22
Current: 1
0.68
1.22
Earnings Yield (Greenblatt) (%) 6.40
ABBV's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ABBV: 6.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABBV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 6.40 Max: 9.8
Current: 6.4
2.4
9.8

More Statistics

Revenue (TTM) (Mil) $23,777
EPS (TTM) $ 3.32
Beta1.60
Short Percentage of Float1.74%
52-Week Range $45.45 - 71.60
Shares Outstanding (Mil)1,617.36

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 25,134 27,494 29,203
EPS ($) 4.75 5.60 6.39
EPS without NRI ($) 4.75 5.60 6.39
EPS Growth Rate
(3Y to 5Y Estimate)
1.85%
» More Articles for NYSE:ABBV

Headlines

Articles On GuruFocus.com
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Gilead, Johnson & Johnson or Roche? Feb 11 2016 
Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Health Care Investor Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? Nov 12 2015 
Companies Return 12-Month Record Amount to Shareholders Sep 25 2015 
Baxalta Vs. AbbVie: Biopharma Spin-Off Battle Aug 20 2015 
JNJ – Should It Be In Your Portfolio? Aug 19 2015 

More From Other Websites
Five Dividend Stocks Hedge Funds Love May 28 2016
3 Stories To Watch At The Year’s Biggest Cancer Conference May 28 2016
7:01 am AbbVie confirms CHMP positive opinion for Humira to treat certain forms of non-infectious... May 28 2016
[$$] Once-Monthly MS Injection Approved in U.S. May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple... May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple... May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple... May 27 2016
Biogen, AbbVie once-monthly MS injection wins U.S. approval May 27 2016
Biogen, AbbVie once-monthly MS injection wins U.S. FDA approval May 27 2016
Morning Technical Breakdown Highlights on Big Drug Makers Stocks May 27 2016
AbbVie's HUMIRA Gets EU Regulator's Positive Opinion To Treat Some Non-Infectious Uveities Types May 27 2016
AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of... May 27 2016
Investors Eager for Gilead to Make Big Moves May 26 2016
High-grade issuance tally for May now at new monthly record May 26 2016
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie May 26 2016
AbbVie to Present at the Jefferies 2016 Healthcare Conference May 26 2016
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well May 25 2016
4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends May 25 2016
AbbVie/Boehringer Report Crohn's Disease Drug Interim Data May 25 2016
Short Sellers Take Mixed Stance on Major Pharma May 25 2016
Richard Bernstein: Why Nobody Wants to Play May 24 2016
[$$] Gilead Names New Operating Chief May 24 2016
AbbVie’s Newly Licensed Drug Scores Against Crohn’s Disease May 24 2016
IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe... May 24 2016
May 24, 2016Innovus Pharma Joins AbbVie Inc. and Eli Lilly & Co. in the Race for the $3 Billion... May 24 2016
US STOCKS-Wall St sells off amid Fed rate hike jitters May 17 2016
US STOCKS-Wall St sells off as rate hike expectations rise May 17 2016
AbbVie to Present at the UBS Global Health Care Conference May 13 2016
Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab)... May 11 2016
AbbVie to Present at the Bank of America Merrill Lynch 2016 Global Health Care Conference Apr 29 2016
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment... Apr 29 2016
Galapagos and AbbVie expand their cystic fibrosis collaboration Apr 29 2016
US STOCKS-Wall St sinks on BOJ fears, Icahn comments Apr 28 2016
US STOCKS-Wall St sinks on BOJ fears, Icahn comments Apr 28 2016
Deals of the day- Mergers and acquisitions Apr 28 2016
US STOCKS-Wall St flounders on BOJ fears as Facebook, M&A boosts wane Apr 28 2016
AbbVie tops Street 1Q forecasts, buying StemCentrx Apr 28 2016
AbbVie Reports First-Quarter 2016 Financial Results Apr 28 2016
AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage... Apr 28 2016
Enanta Announces U.S. FDA has Approved AbbVie’s Supplemental New Drug Application for Use of... Apr 25 2016
AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates Apr 21 2016
CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates Apr 21 2016
AbbVie and Boehringer Ingelheim Announce Global Collaboration on Promising Immunology Compounds Apr 21 2016
AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target Apr 21 2016
argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target Apr 21 2016
AbbVie to Present at the Deutsche Bank 41st Annual Health Care Conference Apr 20 2016
Enanta Announces New Data from AbbVie’s SURVEYOR-1 and SURVEYOR-2 Studies Showing High Sustained... Apr 16 2016
Enanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows... Apr 15 2016
Enanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless of the Presence of... Apr 14 2016
Sean Parker sets up $250 million cancer immunotherapy collaboration Apr 12 2016
FDA approves drug for tough-to-treat type of leukemia Apr 11 2016
AbbVie to Host First-Quarter Earnings Conference Call Apr 07 2016
Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change Apr 06 2016
Factbox - Price hikes shore up revenue for top-selling U.S. drugs Apr 04 2016
Samsung brings in the lawyers for biosimilars push Apr 04 2016
Samsung brings in the lawyers for biosimilars push Apr 04 2016
Samsung brings in the lawyers for biosimilars push Apr 03 2016
Biosimilar drugs could save up to $110 billion by 2020 - IMS Mar 29 2016
UK cost agency rejects leukaemia drug from J&J and AbbVie Mar 01 2016
AbbVie cuts costs, turns profit that meets 4Q expectations Jan 29 2016
AstraZeneca buys most of Acerta for $4 billion to add cancer drug Dec 17 2015
AstraZeneca chases Acerta to secure next cancer drug winner Dec 14 2015
AstraZeneca chases Acerta to secure next cancer drug winner Dec 14 2015
Exclusive: Pfizer negotiating 2-3 percent Allergan break-up fee - sources Nov 19 2015
Exclusive - Beyond Valeant, U.S. payers scrutinize other drugmaker ties to pharmacies Oct 30 2015
US stocks slip as they finish a historically strong October Oct 30 2015
AbbVie beats Street 3Q forecasts, gets a lift from Humira Oct 30 2015
US stocks inch higher as they head for best month since 2011 Oct 30 2015
US stocks waver; on track for best month since 2011 Oct 30 2015
AbbVie beats Street 3Q forecasts Oct 30 2015
FDA warns of deadly liver damage with AbbVie hepatitis drugs Oct 22 2015
Novartis launches first U.S. 'biosimilar' drug at 15 pct discount Sep 03 2015
Drugmaker Shire bids $30 bln for Baxter spin-off Baxalta Aug 04 2015
Less than a year on from AbbVie, there's a delicious irony to Shire's $30bn bid for Baxalta Aug 04 2015
URGENT-US high-grade bond market logs record month for May May 20 2015
Borrowers warned: Don't be fooled by high grade market resilience May 11 2015
US IG WRAP-Qualcomm poised to lead expected deal surge next week May 08 2015
U.S. prescription drug spending rose 13 pct in 2014-IMS report Apr 13 2015
AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal Mar 05 2015
AbbVie boosts cancer drug pipeline with $21 bln Pharmacyclics deal Mar 05 2015
US STOCKS-Wall St little changed after 2-day drop, data Mar 05 2015
US STOCKS-Wall St little changed after 2-day drop, data Mar 05 2015
US STOCKS-Wall St flat after 2-day drop; factory orders due Mar 05 2015
US STOCKS-Wall St to open slightly higher after 2-day fall Mar 05 2015
U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 bln deal Jul 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)